Drugs / autologous bone marrow-derived mononuclear cell
autologous bone marrow-derived mononuclear cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05293873 | Apr 2021 → Mar 2023 | brain injury | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow-derived mononuclear cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293873 ↗ |
| Known as | BM MNCs | “The aim of this study was to evaluate the effects of autologous bone marrow mononuclear cells (BM MNCs) on the QOL of children with CP.” PMID 30107811 ↗ Aug 2018 |
| Known as | bone marrow mononuclear cells | “The aim of this study was to evaluate the effects of autologous bone marrow mononuclear cells (BM MNCs) on the QOL of children with CP.” PMID 30107811 ↗ Aug 2018 |
| Route | Intrathecal | “30 children with CP aged from 2 to 15 years received two intrathecal infusions of BM MNCs” PMID 30107811 ↗ Aug 2018 |